SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Abgenix, Inc. (ABGX)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (322)3/23/2004 1:34:53 PM
From: Icebrg  Read Replies (1) of 590
 
Panitumumab (ABX-EGF)

[From today's AMGN PR. The mAb has at least three different names by now].

Panitumumab (rHuMAb-EGFr) is the first fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFr). It is being evaluated as monotherapy and in combination with other agents for the treatment of various solid tumor cancers in partnership with Abgenix, Inc. In 2004, Amgen initiated pivotal clinical studies in panitumumab as a third-line monotherapy in colorectal cancer patients with a convenient every-other-week dosing regimen.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News